Search

Alterations in hemostasis are linked to the development of ischemic stroke. Intrinsic coagulation pathway activity is typically assessed via Activated Partial Thromboplastin Time (APTT). This study investigates the association between shortened APTT duration and ischemic stroke development. This retrospective case-control study included 85 patients with acute ischemic stroke who were admitted to the Ibb University-affiliated Hospitals, from Jun 2022 to Sept 2023 and 35 control subjects with no history of stroke. Shortened APTT was defined with a duration lower than 28.4 seconds. Multivariate analysis was conducted analyzing factors associated with acute ischemic stroke using Odds Ratio (OR) and 95% Confidence Interval (CI). The mean age of control subjects and acute ischemic stroke cases was 40.69±8.28 years and 62.08±12.19 years, with female gender present in 10 (28.6%) and 41(48.2%) respectively. In the multivariate regression, advanced age (OR: 1.21; 95% CI: 1.13-1.30), APTT less than 28.4 seconds (OR: 7.61; 95% CI: 2.85-20.32), hypertension (OR: 28.74; 95% CI: 6.45-128.04), diabetes mellitus (OR: 10.96; 95% CI: 4.06-29.59), family history of cerebrovascular disease (OR: 13.37; 95% CI:1.73-103.27), current smoking status (OR: 2.48; 95% CI:1.09-5.64), higher cholesterol level (OR: 1.01; 95% CI:1.00-1.02), higher triglycerides level (OR: 1.05; 95% CI:1.03-1.08), and higher LDL level (OR: 1.07 95% CI:1.04-1.10) were predictive factors for acute ischemic stroke occurrence and were statistically significant (all p

Objectives: Parkinson’s disease is the most common neurodegenerative disease. Combining levodopa with other drugs, including decarboxylase inhibitors (DCI) is its most effective treatment. Urinary tract infection (UTI) is the most common cause of hospitalization in Parkinson’s patients, making it crucial to find an appropriate treatment to reduce the incidence of this complication. This study aimed to investigate UTIs in Parkinson’s patients using levodopa with DCI supplements. Methods: In this systematic review and meta-analysis, databases such as PubMed, Scopus, Embase, Cochrane, and Web of Science were searched up to March 2024. Only randomized controlled trials involving Parkinson’s patients were included in the present study. Parkinson’s patients who used levodopa along with carbidopa or benserazide were considered the intervention group, while those who used levodopa with another drug were considered the control group. Results: Nine interventional studies were ultimately analyzed. The relative risk (RR) of UTI in patients taking DCI was 26% lower than those who did not (RR Treatment/Control = 0.74, 95% CI: 0.58-0.95, p = 0.019). Furthermore, observations at different times of follow-up showed that at 13-24 weeks and at > 24 weeks of treatment with DCI, there was a reduction in the incidence of UTI (RR = 0.68, 95% CI: 0.46-1.01 and RR = 0.77, 95% CI: 0.58-1.0, respectively). On the contrary, there was an increase of the risk of UTI in the first 12 weeks of treatment with DCI (RR = 1.11, 95% CI: 0.37-3.33). Conclusions: The results of this study indicated that using DCI drugs is associated with a reduced relative risk of developing UTIs. The beneficial effect of the drug showed after 12 weeks of treatment after an initial negative effect on the risk of UTI.